Sun Pharmaceutical Industries Ltd

Sun Pharma.Inds. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharmaceutical Industries Ltd

₹ 1,952 0.46%
15 Jul - close price
sunpharma.com BSE: 524715 NSE: SUNPHARMA
About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Key Points

Product Offerings:[1][2]
The company produces a range of
generic and specialty medications
for chronic and acute conditions.
Its product portfolio includes
generics, branded generics,
specialty pharmaceuticals,
advanced technology-based
products, antiretrovirals, active
pharmaceutical ingredients (APIs),
and intermediates. It offers medications
in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets,
and capsules. The company offers 27 products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments.[3]

Website BSE NSE
  • Market Cap ₹ 4,68,821 Cr.
  • Current Price ₹ 1,952
  • High / Low ₹ 1,963 / 1,547
  • Stock P/E 159
  • Book Value ₹ 93.2
  • Dividend Yield 0.82 %
  • ROCE 14.8 %
  • ROE 12.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 117%

Cons

  • Stock is trading at 20.9 times its book value
  • The company has delivered a poor sales growth of 8.01% over past five years.
  • Company has high debtors of 179 days.
  • Working capital days have increased from 116 days to 171 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Sensex Nifty 50 BSE 500 BSE Healthcare BSE 100

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
5,948 4,466 5,096 5,074 5,639 4,498 5,122 6,181 7,179 5,595 4,548 5,688 4,924
3,588 3,517 3,710 3,715 3,746 3,737 3,791 4,476 4,120 3,685 3,365 3,929 3,595
Operating Profit 2,361 949 1,386 1,359 1,894 761 1,332 1,705 3,059 1,910 1,184 1,759 1,329
OPM % 40% 21% 27% 27% 34% 17% 26% 28% 43% 34% 26% 31% 27%
-2,817 14 107 7 119 83 95 69 132 -184 73 -79 63
Interest 161 158 194 215 218 216 259 231 232 238 248 244 217
Depreciation 412 415 393 400 393 370 297 303 305 311 336 339 326
Profit before tax -1,030 390 907 751 1,402 258 871 1,240 2,654 1,176 672 1,097 849
Tax % -1% 2% 2% 4% 38% 8% 4% 7% 23% 37% 16% 36% 28%
-1,021 381 889 721 868 238 838 1,156 2,042 745 564 705 609
EPS in Rs -4.25 1.59 3.70 3.01 3.62 0.99 3.49 4.82 8.51 3.11 2.35 2.94 2.54
Raw PDF
Upcoming result date: 31 July 2026

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8,028 7,719 7,684 8,982 10,303 12,532 14,116 15,586 20,812 20,275 22,977 20,755
8,581 8,130 7,559 7,998 8,513 9,815 11,849 12,917 14,389 14,761 16,395 15,921
Operating Profit -552 -410 125 985 1,790 2,717 2,267 2,669 6,423 5,514 6,583 4,833
OPM % -7% -5% 2% 11% 17% 22% 16% 17% 31% 27% 29% 23%
205 367 504 171 23 1,506 93 -624 -2,609 320 634 1,220
Interest 551 574 224 388 541 408 268 388 472 784 954 948
Depreciation 661 464 422 487 553 562 1,236 1,350 1,601 1,601 1,287 1,312
Profit before tax -1,559 -1,082 -17 280 719 3,253 856 307 1,741 3,450 4,976 3,794
Tax % -5% 0% 36% -9% -14% 1% 2% 133% 3% 17% 15% 31%
-1,474 -1,088 -23 306 817 3,211 842 -100 1,691 2,858 4,228 2,623
EPS in Rs -7.12 -4.52 -0.10 1.27 3.40 13.38 3.51 -0.42 7.05 11.91 17.62 10.93
Dividend Payout % -42% -22% -3,677% 157% 81% 30% 214% -2,400% 163% 113% 91% 146%
Compounded Sales Growth
10 Years: 10%
5 Years: 8%
3 Years: 0%
TTM: -10%
Compounded Profit Growth
10 Years: 15%
5 Years: 27%
3 Years: -4%
TTM: -30%
Stock Price CAGR
10 Years: 10%
5 Years: 23%
3 Years: 22%
1 Year: 13%
Return on Equity
10 Years: 8%
5 Years: 10%
3 Years: 14%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 207 241 240 240 240 240 240 240 240 240 240 240
Reserves 22,579 21,650 20,773 22,083 22,604 24,156 26,699 24,348 23,508 23,454 23,660 22,131
6,811 5,829 6,047 6,884 6,437 6,406 7,358 5,074 7,791 11,227 11,947 13,605
7,849 6,547 6,810 7,585 8,434 7,608 9,438 11,103 9,448 6,143 8,031 7,084
Total Liabilities 37,446 34,266 33,869 36,792 37,714 38,410 43,735 40,765 40,987 41,065 43,878 43,060
3,185 3,575 4,039 4,645 4,978 5,229 9,669 9,713 8,712 7,737 7,372 7,613
CWIP 1,091 768 1,100 988 643 597 1,090 829 853 766 1,084 899
Investments 25,876 22,372 19,333 18,355 17,904 17,362 15,537 15,549 12,613 12,430 12,410 12,952
7,294 7,552 9,397 12,804 14,189 15,223 17,438 14,675 18,810 20,132 23,012 21,596
Total Assets 37,446 34,266 33,869 36,792 37,714 38,410 43,735 40,765 40,987 41,065 43,878 43,060

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
149 -1,254 -1,621 -1,171 1,242 1,306 -417 7,636 507 -292 4,252 6,501
2,642 3,640 2,381 1,394 431 1,483 1,452 -2,697 -686 -265 -251 -1,345
-2,674 -2,368 -753 -272 -1,469 -2,871 -1,000 -4,871 169 474 -3,836 -5,230
Net Cash Flow 117 17 7 -50 205 -82 36 68 -9 -84 165 -75
Free Cash Flow -865 -1,804 -2,705 -1,911 658 740 -1,154 6,833 -447 -1,027 3,540 4,987
CFO/OP -62% 220% -669% -89% 71% 60% -8% 205% 15% 1% 67% 143%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 82 94 129 214 178 180 170 99 125 159 186 179
Inventory Days 227 260 256 218 277 210 245 220 240 223 251 287
Days Payable 164 216 229 262 214 170 288 175 188 171 221 236
Cash Conversion Cycle 146 138 155 170 242 220 127 144 177 211 216 230
Working Capital Days -278 -168 -227 -129 -95 -9 62 -26 131 182 -5 171
ROCE % -6% -3% -0% 5% 8% 11% 4% 8% 17% 13% 17% 15%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cumulative ANDA Approvals
count

Log in to view insights

Please log in to see hidden values.

Login
India Formulations Sales
INR Bn
R&D Spend as % of Sales
%
US Formulations Sales
INR Bn
Emerging Markets Formulations Sales
INR Bn
India Sales per Medical Representative
INR Mn
Rest of World Formulations Sales
INR Bn
Global Innovative Medicines Sales
USD Mn
India market share
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48%
16.48% 16.78% 17.08% 17.72% 17.23% 18.01% 18.04% 17.96% 17.26% 16.55% 16.12% 15.94%
19.65% 19.56% 19.42% 18.71% 19.17% 18.48% 18.43% 18.58% 19.38% 20.12% 20.72% 21.00%
0.09% 0.10% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
9.28% 9.05% 8.92% 8.97% 9.00% 8.89% 8.92% 8.86% 8.76% 8.72% 8.57% 8.48%
No. of Shareholders 6,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,9837,23,7707,43,8777,10,9006,90,957

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls